Featured News

View ASX Announcements here.

Starpharma presents additional clinical data for DEP® cabazitaxel in prostate cancer (ASX Announcement)

Sep 12th, 2022

Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.

Read More

Starpharma signs new DEP® agreement with MSD (ASX Announcement)

Aug 10th, 2022

Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Read More

Starpharma to present DEP® at Boston ADC summit (ASX Announcement)

Apr 27th, 2022

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.

Read More

Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Apr 1st, 2022

Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Dr Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022.   ... Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at... Read More



In the media

ADCs Built On Starpharma Delivery Tech To Be Tested By Merck

Aug 22nd, 2022

"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.

Read More

Merck bags chance to test ADCs based on Starpharma delivery tech

Aug 16th, 2022

"Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform", as featured in Fierce Pharma. 

Read More

Starpharma announces new research agreement for DEP drug delivery platform

Aug 11th, 2022

"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune.

Read More

Starpharma (ASX:SPL) signs new DEP research agreement with MSD

Aug 10th, 2022

Following Starpharma's latest announcement, the company was featured in The Market Herald. 

Read More

Sign up to receive news here